RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial

Inclusion Criteria:

1. Subjects must be between 18 and 80 years of age

2. Subject must present with acute myocardial infarction or unstable angina planned forPCI

3. Successful stent implantation (i.e., residual stenosis less than 20%) must be donein culprit lesions and any lesions with ischemia evidence (e.g., QFR equal or lessthan 0.8)

4. Subject must have at least one native non-culprit lesion with visually estimatedstenosis of 40-80% and QFR >0.8

5. Target lesion must have a visually estimated diameter of 2.0-4.0 mm and length of ≤ 50 mm

6. Target lesion must have any two of the intravascular imaging criteria of PB >65%,MLA <3.5 mm^2 (OCT) or 4.0mm^2 (IVUS), FCT <75 μm, or maximal lipid arc >180°

7. Subject must provide written informed consent before any study-related procedure

Exclusion Criteria:

1. Subject has known hypersensitivity or contraindication to any of the study drugs (including all asprin, P2Y12 inhibitors, one or more components of the studydevices, including paclitaxel, etc) that cannot be adequately pre-medicated

2. Subject is receiving immunosuppressant therapy or has known immunosuppressive orsevere autoimmune disease that requires chronic immunosuppressive therapy (e.g.,human immunodeficiency virus, systemic lupus erythematosus, etc.)

3. Hypotension, shock, or need for mechanical support or intravenous vasopressors;

4. Creatinine clearance ≤30 ml/min/1.73 m^2 (as calculated by MDRD formula forestimated GFR)

5. Left ventricular ejection fraction<30% by the most recent imaging test within 30days before procedure (echo, MRI, contrast left ventriculography or others)

6. Life expectancy <2 years for any

7. Subject is currently participating in another investigational drug or deviceclinical study that has not yet completed its primary endpoint

8. Presence of other anatomic or comorbid conditions, or other medical, social, orpsychological conditions that, in the investigator's opinion, could limit thesubject's ability to participate in the clinical investigation or to comply withfollow-up requirements, or impact the scientific soundness of the clinicalinvestigation results.

9. The target lesion is located within 10 mm of the proximal or distal of stent

10. The target lesion cannot be in the left main coronary artery

11. The target lesion is located in a bifurcation lesion (i.e., the diameter of thebranch vessels is >2 mm with >50% of stenosis)

12. The target lesion is located in severe calcification or tortuosity of vessels

13. The target lesion involved in the ostium of LAD, LCX or RCA (within 3 mm of theostium)

14. The target lesion is located within the bypass graft artery